Tulin Shekar

588 total citations
33 papers, 251 citations indexed

About

Tulin Shekar is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Tulin Shekar has authored 33 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 16 papers in Pulmonary and Respiratory Medicine and 9 papers in Epidemiology. Recurrent topics in Tulin Shekar's work include Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (13 papers) and Pneumonia and Respiratory Infections (9 papers). Tulin Shekar is often cited by papers focused on Asthma and respiratory diseases (20 papers), Respiratory and Cough-Related Research (13 papers) and Pneumonia and Respiratory Infections (9 papers). Tulin Shekar collaborates with scholars based in United States, Canada and Colombia. Tulin Shekar's co-authors include Ariel Teper, Bruce M. Prenner, Eli O. Meltzer, David I. Bernstein, Davis Gates, Luwy Musey, William E. Berger, Bobby Q. Lanier, Hendrik Nolte and Camilo J. Acosta and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Infectious Diseases.

In The Last Decade

Tulin Shekar

31 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tulin Shekar United States	9	147	96	88	71	28	33	251
Cecilia Ahlström‐Emanuelsson Sweden	6	127 0.9×	100 1.0×	39 0.4×	13 0.2×	17 0.6×	8	170
Wirach Chitsuthipakorn Thailand	11	149 1.0×	182 1.9×	43 0.5×	20 0.3×	41 1.5×	32	317
Dichapong Kanjanawasee Thailand	9	111 0.8×	138 1.4×	35 0.4×	16 0.2×	39 1.4×	23	240
Pedro Ojeda Spain	8	93 0.6×	113 1.2×	26 0.3×	6 0.1×	11 0.4×	11	176
Sarah Dudley United Kingdom	5	147 1.0×	42 0.4×	98 1.1×	80 1.1×	3 0.1×	5	271
Cristina Boccabella Italy	6	52 0.4×	27 0.3×	40 0.5×	22 0.3×	2 0.1×	14	115
Agamemnon Bakakos Greece	7	134 0.9×	32 0.3×	96 1.1×	20 0.3×	1 0.0×	21	182
Nkiruka Erekosima United States	7	411 2.8×	432 4.5×	82 0.9×	4 0.1×	27 1.0×	7	500
A. M. Plaza Spain	8	60 0.4×	88 0.9×	23 0.3×	12 0.2×		14	186
Hagen Ott Germany	5	54 0.4×	79 0.8×	39 0.4×	18 0.3×		6	227

Countries citing papers authored by Tulin Shekar

Since Specialization

Citations

This map shows the geographic impact of Tulin Shekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tulin Shekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tulin Shekar more than expected).

Fields of papers citing papers by Tulin Shekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tulin Shekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tulin Shekar. The network helps show where Tulin Shekar may publish in the future.

Co-authorship network of co-authors of Tulin Shekar

This figure shows the co-authorship network connecting the top 25 collaborators of Tulin Shekar. A scholar is included among the top collaborators of Tulin Shekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tulin Shekar. Tulin Shekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weinberg, Aaron S., Spyros Chalkias, Gretchen Tamms, et al.. (2025). Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines. 13(2). 192–192.

Buchwald, Ulrike K., Laura L. Hammitt, Jason J. LeBlanc, et al.. (2025). The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay. Vaccine. 62. 127453–127453.

Nolan, Katrina M., Robert L. Burton, Tulin Shekar, et al.. (2023). The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C. Human Vaccines & Immunotherapeutics. 19(2). 2235238–2235238. 6 indexed citations

Hammitt, Laura L., Dean Quinn, Ewa Janczewska, et al.. (2023). Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. Human Vaccines & Immunotherapeutics. 19(1). 2177066–2177066. 4 indexed citations

Wilck, Marissa B., Oliver A. Cornely, Catherine Cordonnier, et al.. (2023). A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM). Clinical Infectious Diseases. 77(8). 1102–1110. 6 indexed citations

Simon, Jakub K., Nina Breinholt Stærke, Ron Dagan, et al.. (2022). Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). Vaccine. 40(9). 1342–1351. 8 indexed citations

Zhang, Xiaoli, Tulin Shekar, Davis Gates, et al.. (2020). Serious Asthma Outcomes and Asthma Exacerbations with Maintenance on Inhaled Corticosteroid (Mometasone Furoate)/Long-Acting Beta Agonist (Formoterol) Combination Compared to Step Down to Mometasone Monotherapy. The Journal of Allergy and Clinical Immunology In Practice. 8(5). 1634–1644.e1. 1 indexed citations

Platt, Heather, David Greenberg, Bruce Tapiéro, et al.. (2020). A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. The Pediatric Infectious Disease Journal. 39(8). 763–770. 43 indexed citations

Shekar, Tulin, et al.. (2018). Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. Journal of Allergy and Clinical Immunology. 143(4). 1395–1402. 17 indexed citations

10.

Machiels, Jean‐Pascal, Lisa Licitra, Danny Rischin, et al.. (2017). KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. Journal of Clinical Oncology. 35(15_suppl). TPS6090–TPS6090. 10 indexed citations

11.

Ciprero, Karen L., Н. И. Брико, Tulin Shekar, et al.. (2016). Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects. Human Vaccines & Immunotherapeutics. 12(8). 2142–2147. 7 indexed citations

12.

Amar, Niran J., et al.. (2016). Mometasone Furoate (MF) Improves Lung Function in Pediatric Asthma: A Dose-Ranging Study of MF Metered-Dose Inhaler (MDI). Journal of Allergy and Clinical Immunology. 137(2). AB214–AB214. 1 indexed citations

13.

Nolte, Hendrik, Ian Pavord, Vibeke Backer, et al.. (2013). Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma. Respiratory Medicine. 107(5). 656–664. 26 indexed citations

14.

Kerwin, Edward, et al.. (2012). Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. SHILAP Revista de lepidopterología. 2 indexed citations

15.

Kerwin, Edward, et al.. (2011). Quality of Life Following 26 Weeks of Mometasone Furoate/Formoterol Therapy: Results From Two Phase Three Trials in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease. CHEST Journal. 140(4). 558A–558A. 2 indexed citations

16.

Prenner, Bruce M., Bobby Q. Lanier, David I. Bernstein, Tulin Shekar, & Ariel Teper. (2010). Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 125(6). 1247–1253.e5. 26 indexed citations

17.

Sullivan, Patrick W., Prakash Navaratnam, Richard Lorber, & Tulin Shekar. (2010). The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis. Current Medical Research and Opinion. 26(6). 1389–1397. 2 indexed citations

18.

Gross, Gary N., et al.. (2010). Impact of Concomitant Administration of Mometasone Furoate and Oxymetazoline Nasal Sprays vs Either Drug Alone or Placebo on Quality of Life in Patients with Seasonal Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 125(2). AB174–AB174. 4 indexed citations

19.

Nayak, Anjuli, et al.. (2010). Tolerability of Concomitant Administration of Mometasone Furoate and Oxymetazoline Nasal Sprays Administered Once Daily vs Oxymetazoline Twice Daily, Mometasone Furoate Once Daily, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 125(2). AB175–AB175. 5 indexed citations

20.

Prenner, Bruce M., Bobby Q. Lanier, David I. Bernstein, Tulin Shekar, & Ariel Teper. (2010). Reply. Journal of Allergy and Clinical Immunology. 127(1). 289–289. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact